Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
0.8410
-0.0342 (-3.91%)
At close: Nov 17, 2026, 4:00 PM EST
0.922949
+0.0819 (9.74%)
After-hours: Nov 17, 2026, 4:17 PM EST
Allarity Therapeutics Employees
As of December 31, 2025, Allarity Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year. That makes Allarity Therapeutics the 40,701st largest employer in the world and 6,143rd in the United States.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$43,750
Profits / Employee
-$1,966,000
Market Cap
13.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2024 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2023 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2022 | 9 | -4 | -30.77% | 9 | 0 |
| Dec 31, 2021 | 13 | -1 | -7.14% | 13 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| Seres Therapeutics | 66 |
| Acumen Pharmaceuticals | 61 |
| aTyr Pharma | 60 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Jasper Therapeutics | 22 |
| Actuate Therapeutics | 12 |
ALLR News
- 1 day ago - Allarity expands Phase 2 stenoparib trial to three ovarian cancer cohorts - TheFly
- 1 day ago - Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts - GlobeNewsWire
- 4 days ago - Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance - GlobeNewsWire
- 18 days ago - Allarity secures first commercial agreement under CLIA strategy - TheFly
- 18 days ago - Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue - GlobeNewsWire
- 6 weeks ago - Allarity updates on recent advances in Drug Response Predictor technology - TheFly
- 6 weeks ago - Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development - GlobeNewsWire
- 7 weeks ago - Allarity expands lab capabilities to include proteomics, cell line research - TheFly